FDA expands import block on Olympus endoscopes

The Food and Drug Administration announced Tuesday that it is halting shipment of 5 models of Olympus endoscopes made in Japan, adding to a June 2025 alert that barred 58 devices. The decision reflects the agency’s ongoing effort to protect patients from equipment that may not meet established safety standards.

The latest import alert broadens the 2025 action to cover specific enteroscopes and ingestible telemetric gastrointestinal capsule imaging systems, citing ongoing concerns about unresolved quality-system regulation violations despite the firm’s remediation efforts. By expanding the scope, regulators aim to close gaps that could allow substandard products to enter the market.

Refused devices include tools for diagnostic and therapeutic procedures in the urinary and respiratory tracts, abdomen, pelvis and small intestine, as well as automated endoscope reprocessors. The agency noted that some of these items may already have been recalled, indicating that previous corrective actions may not have fully addressed the underlying problems.

The regulator clarified that equipment already cleared for use in U.S. facilities may remain operational provided no performance problems are reported. Hospitals that have already installed the affected models are advised to monitor functionality closely and report any adverse events promptly.

A company spokesperson said the alerts are not expected to materially affect customers or the consolidated financial results for the fiscal year ending March 31 2027, and they do not impact imports outside the United States. The statement emphasized that the firm continues to support existing users while working to resolve the compliance issues.

FDA expands import block on Olympus devices

The agency’s warning letter, dated October 7, detailed quality-system and medical-device reporting violations uncovered during inspections of six Olympus sites, extending a series of enforcement actions that began in 2022. Inspectors highlighted gaps in documentation, testing, and risk assessment that could compromise patient safety.

At the Shirakawa, Japan, plant, investigators found the manufacturer failed to validate device design and omitted catastrophic hazards such as air embolism, arrhythmia and patient death from its risk-management report, even after a fatal incident. The omission suggests a shortfall in the firm’s obligation to anticipate worst-case scenarios.

The Minnesota facility reworked and distributed nonconforming devices without sufficient justification, including a case where a needle detachment may have contributed to a patient’s death during explant surgery to retrieve the detached component. This incident shows the potential consequences of releasing products that have not undergone thorough verification.

In Hachioji, Japan, the firm did not identify corrective actions after the agency requested additional information about a death linked to a bronchovideoscope, leaving the root cause unresolved. The lack of a clear remediation plan prompted regulators to maintain the import block.